Using engineered nucleases, such as Zinc Finger Nucleases (ZFNs) or 
Transcription Activator-Like Effector Nucleases (TALENs), to make targeted 
genomic modifications has become a common technique to create new model 
organisms and custom cell lines, and has shown great promise for disease 
treatment. However, these nucleases have the potential for off-target cleavage 
that could confound interpretation of experimental results and be detrimental 
for therapeutic use. Here, we describe a method to test for nuclease cleavage at 
potential off-target sites predicted by bioinformatics models.